Scholar Rock initiated with a Buy at BofA on SMA therapy potential

As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Scholar Rock (SRRK) with a Buy rating and $53 price target Scholar Rock is developing an IV-administered adjunctive antibody therapy, apitegromab, for spinal muscular atrophy, notes the analyst, who sees “significant unmet need” remaining in the space given that currently approved SMA therapies are not curative and disease progression persists. Aapitegromab is the only myostatin-targeting therapy to show a statistically significant benefit in motor function in a pivotal trial, says the analyst, who models $2B in 2037 risk-adjusted peak sales in SMA.